However, outcomes may be different between tumor types, i.e., immune modulators such as PD-1 inhibitors or VA may be more effective in cancers like NSCLC because these tumors often have a higher mutational burden, producing more neo-antigens that can trigger an immune response [14]. This evidence concerns the gene PDCD1 and cancer.